IgA nephropathy: trials for referral
105 open trials in the registries we read. Each row links to its registry record.
Registry data only. Frontlight does not judge whether a patient can take part: the trial team decides.
Where the open trials are
Type a city to sort by distance. The distance is worked out in your browser; the city is not sent anywhere.
105 trials shown
Phase 34 sites
RecruitingUnited States
NCT07902817
A Phase 3 Blinded Study of JADE101 in Participants With Immunoglobulin A Nephropathy
Jade Biosciences, Inc.
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govPhase 21 site
RecruitingChina
NCT05517980
Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of KP104 to Treat Glomerulonephritis
Kira Pharmacenticals (US), LLC.
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govNo phase1 site
Not yet recruitingChina
NCT07901764
MYTP01 for Immune-Mediated Diseases
Zhejiang Provincial People's Hospital
Registry updated 2 Nov 2026
Registry record: ClinicalTrials.govPhase 220 sites
RecruitingAustralia, South Korea, New Zealand, Taiwan, United States
NCT07541287
A Study of JADE101 in Participants With Immunoglobulin A Nephropathy
Jade Biosciences, Inc.
Registry updated 30 Oct 2026
Registry record: ClinicalTrials.govPhase 333 sites
RecruitingBelgium, Czechia, Germany, Spain, France, Greece
2024-519638-22-00
A clinical trial to learn about the long-term safety of FUB523 (zigakibart) in people with immunoglobulin A (IgA) nephropathy who have completed previous zigakibart trials
Novartis Pharma AG
Registry updated 30 Oct 2026
Registry record: EU CTISPhase 229 sites
RecruitingBelgium, Czechia, Spain, Italy, Japan, Poland
NCT07773727
A Study to Evaluate the Effect of ARGX-121 on the Change in Proteinuria in Adult Participants With IgAN
argenx
Registry updated 27 Oct 2026
Registry record: ClinicalTrials.govPhase 11 site
Not yet recruitingChina
NCT07897240
A Food-Effect Study of Budesonide Delayed Release Tablet (D23A) in Healthy Chinese Participants
Triastek, lnc.
Registry updated 27 Oct 2026
Registry record: ClinicalTrials.govPhase 3182 sites
RecruitingArgentina, Austria, Australia, Canada, Switzerland, China
NCT06963827
A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
Takeda
Registry updated 23 Oct 2026
Registry record: ClinicalTrials.govPhase 20 sites
Not yet recruiting
NCT07889362
A Study to Learn About the Effects of Felzartamab on the Kidneys of Adults With Immunoglobulin A Nephropathy (IgAN)
Biogen
Registry updated 22 Oct 2026
Registry record: ClinicalTrials.govPhase 30 sites
Not yet recruiting
NCT07890909
A Phase 3b Study of Participant Experience on Povetacicept Administered Via Autoinjector as Compared to Sibeprenlimab Administered Via Prefilled Syringe
Vertex Pharmaceuticals Incorporated
Registry updated 22 Oct 2026
Registry record: ClinicalTrials.govPhase 41 site
Not yet recruitingChina
NCT07888335
Efficacy and Safety of Obinutuzumab Beta in Primary IgA Nephropathy With Active Pathological Lesions
Ruijin Hospital
Registry updated 22 Oct 2026
Registry record: ClinicalTrials.govPhase 11 site
Not yet recruitingChina
NCT07886476
IBI3034 Study in Healthy Adults and Patients With Primary IgA Nephropathy
Innovent Biologics (Suzhou) Co. Ltd.
Registry updated 21 Oct 2026
Registry record: ClinicalTrials.govPhase 230 sites
RecruitingBrazil, China, Czechia, Germany, Spain, Italy
NCT07146906
A Study to Assess the Effects of Zigakibart on IgA Nephropathy.
Novartis Pharmaceuticals
Registry updated 21 Oct 2026
Registry record: ClinicalTrials.govNo phase1 site
By invitation onlyUnited Kingdom
NCT07649538
Mediators of Loin Pain in IgA Nephropathy
University of Leicester
Registry updated 20 Oct 2026
Registry record: ClinicalTrials.govPhase 232 sites
RecruitingAustralia, Spain, United Kingdom, Hong Kong SAR China, Italy, South Korea
NCT06989359
Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
ADARx Pharmaceuticals, Inc.
Registry updated 20 Oct 2026
Registry record: ClinicalTrials.govPhase 34 sites
By invitation onlyUnited States
NCT07807995
A Phase 3 Open-Label Study of Long-term Treatment With Povetacicept in Adults With Immunoglobulin A Nephropathy
Vertex Pharmaceuticals Incorporated
Registry updated 19 Oct 2026
Registry record: ClinicalTrials.govPhase 30 sites
Not yet recruiting
NCT07770815
Trial of Sibeprenlimab in Children and Adolescents With Immunoglobulin A Nephropathy (IgAN)
Otsuka Pharmaceutical Development & Commercialization, Inc.
Registry updated 15 Oct 2026
Registry record: ClinicalTrials.govPhase 317 sites
RecruitingChina, Spain, France, Japan, South Korea, Taiwan
NCT07498335
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
Novartis Pharmaceuticals
Registry updated 15 Oct 2026
Registry record: ClinicalTrials.govPhase 3264 sites
RecruitingArgentina, Australia, Belgium, Bulgaria, Brazil, Canada
NCT06935357
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
Biogen
Registry updated 14 Oct 2026
Registry record: ClinicalTrials.govPhase 22 sites
RecruitingUnited States
NCT06676579
Avacopan in Crescentic Immunoglobulin A Nephropathy (IgAN)
Mayo Clinic
Registry updated 9 Oct 2026
Registry record: ClinicalTrials.govPhase 218 sites
RecruitingFrance
NCT06350630
Therapeutic Effect of Hydroxychloroquine on Immunoglobulin A (IgA) Nephropathy Course QUIgAN Study
Centre Hospitalier Universitaire de Saint Etienne
Registry updated 9 Oct 2026
Registry record: ClinicalTrials.govPhase 31 site
Not yet recruitingItaly
2026-525677-39-00
An open-label, single-arm, multicenter roll-over extension program (REP) to characterize the long-term safety and tolerability of iptacopan (LNP023) in patients who have completed a clinical trial (parent study) in the iptacopan pediatric program.
Novartis Pharma AG
Registry updated 6 Oct 2026
Registry record: EU CTISPhase 3134 sites
RecruitingArgentina, Australia, Belgium, Brazil, Canada, Chile
NCT04557462
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
Novartis Pharmaceuticals
Registry updated 5 Oct 2026 · The registries disagree on the status
Registry record: ClinicalTrials.govPhase 24 sites
RecruitingBrazil, United States
NCT06419205
A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G
Akebia Therapeutics
Registry updated 1 Oct 2026
Registry record: ClinicalTrials.govPhase 30 sites
Not yet recruiting
NCT07850752
A Study of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patients With Primary IgA Nephropathy
Novartis Pharmaceuticals
Registry updated 30 Sept 2026
Registry record: ClinicalTrials.govPhase 41 site
Not yet recruitingUnited States
NCT07820995
Mechanistic Evaluation of Atrasentan in Patients With IgA Nephropathy (IgAN)
University of Illinois Chicago
Registry updated 21 Sept 2026
Registry record: ClinicalTrials.govPhase 28 sites
RecruitingAustralia
NCT07606352
Safety and Efficacy of STL303 In Patients With Primary Immunoglobulin A (IgA) Nephropathy
Sitala Bio LTD
Registry updated 17 Sept 2026
Registry record: ClinicalTrials.govNo phase1 site
RecruitingChina
NCT07822100
To Assess the Efficacy and Safety of Utilizing Galactose-deficient IgA1 Biomarker Changes to Guide Pathogenic IgA-targeted Therapeutic Strategies
Hong Zhang
Registry updated 16 Sept 2026
Registry record: ClinicalTrials.govNo phase1 site
RecruitingChina
NCT03001947
IgA Nephropathy Registration Initiative of High Quality (INSIGHT)
Sun Yat-sen University
Registry updated 15 Sept 2026
Registry record: ClinicalTrials.govNo phase5 sites
RecruitingChina
NCT05190848
Correlation of Microbiome and Metabonomics With IgA Nephropathy
Guangdong Provincial People's Hospital
Registry updated 14 Sept 2026
Registry record: ClinicalTrials.gov
The same sites as a list
- China54 open trials
- United States26 open trials
- South Korea12 open trials
- Spain12 open trials
- United Kingdom12 open trials
- Australia11 open trials
- France11 open trials
- Taiwan10 open trials
- Italy10 open trials
- Japan9 open trials
- Germany7 open trials
- Argentina7 open trials
- Poland6 open trials
- Malaysia6 open trials
- Hong Kong SAR China5 open trials
- Brazil5 open trials
- India5 open trials
- Belgium4 open trials
- Czechia4 open trials
- Israel4 open trials
- Croatia3 open trials
- Netherlands3 open trials
- Sweden3 open trials
- Canada3 open trials
- Russia3 open trials
- New Zealand2 open trials
- Greece2 open trials
- Singapore2 open trials
- Norway2 open trials
- Hungary2 open trials
- Portugal2 open trials
- Philippines2 open trials
- Colombia2 open trials
- Mexico2 open trials
- Slovakia2 open trials
- Vietnam2 open trials
- Saudi Arabia2 open trials
- Sri Lanka2 open trials
- Bulgaria1 open trials
- South Africa1 open trials
- Chile1 open trials
- Denmark1 open trials
- Slovenia1 open trials
- Thailand1 open trials
- Bangladesh1 open trials
- Switzerland1 open trials
Who treats this
Institutions with trials or publications in this disease (OpenAlex, registries). Institutions only, no people.
Cambridge University Hospitals NHS Foundation Trust
Cambridge, United Kingdom
0 trials · 9 publications · ROR
Centre Hospitalier Universitaire de Saint-Étienne
Saint-Etienne, France
6 trials · 8 publications · ROR
Chinese Academy of Medical Sciences & Peking Union Medical College
Beijing, China
0 trials · 33 publications · ROR
First Affiliated Hospital of Henan University of Traditional Chinese Medicine
Zhengzhou, China
0 trials · 8 publications · ROR
Institute of Post Graduate Medical Education and Research
Kolkata, India
0 trials · 11 publications · ROR
Ministry of Education of the People's Republic of China
Beijing, China
0 trials · 7 publications · ROR
Otsuka Pharmaceutical Development & Commercialization, Inc. (United States)
Princeton, United States
0 trials · 15 publications · ROR
Post Graduate Institute of Medical Education and Research
Chandigarh, India
0 trials · 9 publications · ROR
Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital
Chengdu, China
4 trials · 19 publications · ROR
The First Affiliated Hospital, Sun Yat-sen University
Guangzhou, China
3 trials · 18 publications · ROR
The Ohio State University Wexner Medical Center
Columbus, United States
1 trials · 18 publications · ROR
University Hospitals of Leicester NHS Trust
Leicester, United Kingdom
0 trials · 27 publications · ROR
University of Electronic Science and Technology of China
Chengdu, China
0 trials · 18 publications · ROR
University of North Carolina at Chapel Hill
Chapel Hill, United States
1 trials · 13 publications · ROR
What changed in the last 7 days
Registry facts, one per line, newest first.
No registry change in the last 7 days.
Results card
Trials that finished or stopped in the last 3 years, with the reason the registry gives and linked publications.
No phaseEnded 1 Sept 2026
Phase 3Ended 19 Aug 2026
Completed406 participants
NCT03762850
A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy
No phaseEnded 1 Jul 2026
Completed6286 participants
NCT07757048
A Study of Treatment Patterns and Real-World Outcomes in IgA Nephropathy Patients in the United States
Phase 1/2Ended 10 Jun 2026
Completed103 participants
NCT03945318
Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN)
Phase 2Ended 15 May 2026
Completed87 participants
NCT06670352
Phase II Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN
No phaseEnded 5 May 2026
Phase 2Ended 23 Apr 2026
Phase 1Ended 6 Mar 2026
No phaseEnded 31 Dec 2025
Phase 1Ended 15 Dec 2025
Completed17 participants
NCT05174221
A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy
No phaseEnded 26 Nov 2025
No phaseEnded 31 Oct 2025
Phase 2Ended 29 Oct 2025
Completed54 participants
NCT05834738
Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy
Phase 2Ended 17 Oct 2025
Phase 3Ended 19 Sept 2025
Completed518 participants
NCT04578834
Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients
Phase 3Ended 15 Sept 2025
Completed102 participants
2024-511067-29-00
Study of efficacy and safety of LNP023 in primary IgA nephropathy patients.
Phase 1/2Ended 10 Sept 2025
Completed62 participants
NCT05083364
Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease
No phaseEnded 30 Aug 2025
Phase 2Ended 15 Aug 2025
Completed316 participants
NCT05016323
A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Primary IgA Nephropathy.
Phase 1Ended 22 Jul 2025
Completed16 participants
NCT07035665
A Clinical Study to Evaluate the Effect of Food on the Pharmacokinetic Profiles of HRS-5965 Capsules in Healthy Subjects
Phase 2Ended 15 Jul 2025
Completed87 participants
NCT04564339
Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)
Phase 4Ended 15 Jan 2025
Phase 2Ended 14 Nov 2024
Completed35 participants
NCT05097989
Phase 2 Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)
Phase 2Ended 25 Oct 2024
Completed48 participants
NCT05856760
A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN
Phase 1Ended 10 Sept 2024
No phaseEnded 5 Sept 2024
Completed200 participants
NCT06589752
Replication of the NefIgArd Trial of TRF-budesonide in Primary IgAN
Phase 3Ended 17 Jul 2024
Completed21 participants
NCT05534919
Efficacy and Safety in Chinese Patients with Immunoglobulin a Nephropathy (IgAN) Who Have Completed Study Nef-301
Phase 2Ended 6 May 2024
Completed54 participants
NCT05065970
Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy
Phase 2Ended 11 Apr 2024
No phaseEnded 31 Mar 2024
Completed245 participants
NCT06460987
Study of the Clinical Efficacy and Safety of Finerenone for the Treatment of IGA Nephropathy
Phase 4Ended 30 Mar 2024
Phase 3Ended 26 Feb 2024
Completed119 participants
NCT04541043
Efficacy and Safety in Patients With Primary IgA Nephropathy Who Have Completed Study Nef-301 (Nefigard-OLE)
Phase 1Ended 25 Jan 2024
Phase 3Ended 12 Jan 2024
No phaseEnded 31 Dec 2023
Completed70000 participants
NCT07607002
Assessing the Global Burden of IgA Nephropathy (IgAN) in Patients Receiving Hemodialysis: A Real-World Study Using DOPPS Data
No phaseEnded 31 Dec 2023
Completed15 participants
NCT05182775
A Clinical Research on the Use of Fecal Bacteria Transplantation for Treatment of IgA Nephropathy
Not medical advice. fetched 4 Nov 2026